These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37774393)
21. Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer. Gregson SJ; Pugh K; Patel N; Afif-Rider S; Vijayakrishnan B; Santos K; Riedl J; Hutchinson I; Kang GD; Chooi KP; Beard R; Adams L; Barry CS; Ball K; Masterson LA; McFarlane M; Hartley JA; Howard PW Mol Cancer Ther; 2022 Sep; 21(9):1439-1448. PubMed ID: 35793464 [TBL] [Abstract][Full Text] [Related]
22. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164 [TBL] [Abstract][Full Text] [Related]
23. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates. Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528 [TBL] [Abstract][Full Text] [Related]
24. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry. Inoue K; Mochizuki T; Kasamori N; Komori T Bioanalysis; 2022 Dec; 14(24):1533-1545. PubMed ID: 36825963 [TBL] [Abstract][Full Text] [Related]
25. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517 [TBL] [Abstract][Full Text] [Related]
26. Imaged capillary isoelectric focusing method development for charge variants of high DAR ADCs. Leng C; Sun S; Lin W; Pavon JA; Gennaro L; Gunawan RC; Bu X; Yang T; Li S Anal Chim Acta; 2024 Nov; 1328():343176. PubMed ID: 39266202 [TBL] [Abstract][Full Text] [Related]
27. Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control. Tang Y; Tang F; Yang Y; Zhao L; Zhou H; Dong J; Huang W Sci Rep; 2017 Aug; 7(1):7763. PubMed ID: 28798339 [TBL] [Abstract][Full Text] [Related]
29. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513 [TBL] [Abstract][Full Text] [Related]
30. Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates. Kaempffe A; Dickgiesser S; Rasche N; Paoletti A; Bertotti E; De Salve I; Sirtori FR; Kellner R; Könning D; Hecht S; Anderl J; Kolmar H; Schröter C J Pharm Sci; 2021 Dec; 110(12):3776-3785. PubMed ID: 34363839 [TBL] [Abstract][Full Text] [Related]
31. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298 [TBL] [Abstract][Full Text] [Related]
32. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates. Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988 [TBL] [Abstract][Full Text] [Related]
33. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma. Wei C; Zhang G; Clark T; Barletta F; Tumey LN; Rago B; Hansel S; Han X Anal Chem; 2016 May; 88(9):4979-86. PubMed ID: 27075639 [TBL] [Abstract][Full Text] [Related]
34. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates. Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707 [TBL] [Abstract][Full Text] [Related]
35. Current methods for the synthesis of homogeneous antibody-drug conjugates. Sochaj AM; Świderska KW; Otlewski J Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886 [TBL] [Abstract][Full Text] [Related]
36. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587 [TBL] [Abstract][Full Text] [Related]
37. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323 [TBL] [Abstract][Full Text] [Related]
38. Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) for Breast Cancer Treatment. Nagaraja Shastri P; Zhu J; Skidmore L; Liang X; Ji Y; Gu Y; Tian F; Yao S; Xia G Mol Cancer Ther; 2020 Sep; 19(9):1822-1832. PubMed ID: 32499302 [TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359 [TBL] [Abstract][Full Text] [Related]
40. A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy. Yurkovetskiy AV; Yin M; Bodyak N; Stevenson CA; Thomas JD; Hammond CE; Qin L; Zhu B; Gumerov DR; Ter-Ovanesyan E; Uttard A; Lowinger TB Cancer Res; 2015 Aug; 75(16):3365-72. PubMed ID: 26113086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]